IL95512A0 - Brain derived neurotrophic factor - Google Patents

Brain derived neurotrophic factor

Info

Publication number
IL95512A0
IL95512A0 IL95512A IL9551290A IL95512A0 IL 95512 A0 IL95512 A0 IL 95512A0 IL 95512 A IL95512 A IL 95512A IL 9551290 A IL9551290 A IL 9551290A IL 95512 A0 IL95512 A0 IL 95512A0
Authority
IL
Israel
Prior art keywords
bdnf
nucleic acid
ngf
acid sequences
relates
Prior art date
Application number
IL95512A
Other languages
English (en)
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/400,591 external-priority patent/US5180820A/en
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Publication of IL95512A0 publication Critical patent/IL95512A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL95512A 1989-08-30 1990-08-28 Brain derived neurotrophic factor IL95512A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor
US07/570,657 US5229500A (en) 1989-08-30 1990-08-20 Brain derived neurotrophic factor

Publications (1)

Publication Number Publication Date
IL95512A0 true IL95512A0 (en) 1991-06-30

Family

ID=27017110

Family Applications (1)

Application Number Title Priority Date Filing Date
IL95512A IL95512A0 (en) 1989-08-30 1990-08-28 Brain derived neurotrophic factor

Country Status (20)

Country Link
US (2) US5229500A (fr)
EP (1) EP0440777B1 (fr)
KR (1) KR100188189B1 (fr)
CN (1) CN1124343C (fr)
AT (1) ATE148921T1 (fr)
AU (1) AU647412B2 (fr)
CA (1) CA2040412C (fr)
DE (1) DE69029934T2 (fr)
DK (1) DK0440777T3 (fr)
ES (1) ES2098271T3 (fr)
FI (1) FI105342B (fr)
HK (1) HK1006578A1 (fr)
IE (1) IE903128A1 (fr)
IL (1) IL95512A0 (fr)
LV (1) LV10725B (fr)
NO (1) NO303584B1 (fr)
PT (1) PT95152B (fr)
SG (1) SG46954A1 (fr)
SK (1) SK279668B6 (fr)
WO (1) WO1991003568A1 (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844072A (en) 1992-05-26 1998-12-01 University Of California Antibiotic cryptdin peptides and methods of their use
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
WO1992020797A1 (fr) * 1991-05-20 1992-11-26 Case Western Reserve University Facteur neurotrophique, sa preparation et ses utilisations
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
CA2112799A1 (fr) * 1991-07-03 1993-01-21 Stephen P. Squinto Methode et systeme d'analyse de l'activite des neurotrophines
PT100501A (pt) * 1991-07-10 1993-09-30 Regeneron Pharma Composicoes farmaceuticas a base de um membro da familia de moleculas de bdnf/nt-3/ngf, processo para promover a sobrevivencia,crescimentoe/ou diferenciacao de neuronios motores in vitro e de diagnostico, e processo de ensaio de um agente de teste.
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
AU677951B2 (en) * 1992-02-14 1997-05-15 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
WO1993024529A1 (fr) * 1992-06-04 1993-12-09 University Of Southern California Facteur neurotrophique derive de l'epithelium retinien pigmente
EP0573904B1 (fr) * 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Agent thérapeutique pour neutropénie
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
ATE194658T1 (de) * 1992-09-03 2000-07-15 Univ California Das dorsalgewebe beeinflussender faktor
JP3431153B2 (ja) * 1992-09-03 2003-07-28 リジエネロン・フアーマシユーテイカルズ・インコーポレーテツド 背側組織作用因子及び組成物
US20040224409A1 (en) * 1992-09-25 2004-11-11 Laurent Pradier Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
EP0632008B1 (fr) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Dérivés de l'acide pentanoique
AU7605394A (en) * 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995012686A1 (fr) * 1993-11-03 1995-05-11 Cephalon, Inc. Procede de criblage de composes capables de modifier la teneur en tyrosine hydroxylase de cellules intactes dans des cutures
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
AU708529B2 (en) * 1994-11-10 1999-08-05 University Of Kentucky Research Foundation, The Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US6743628B1 (en) * 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
EP0938499A1 (fr) * 1996-07-19 1999-09-01 Amgen Inc. Analogues de proteines cationiques
HU222666B1 (hu) 1996-11-15 2003-09-29 Genentech, Inc. Eljárás neuorotrofinok tisztítására
KR20000070357A (ko) 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제
AU1179699A (en) * 1997-11-11 1999-05-31 Universiteit Utrecht Genes with restricted expression in mesencephalic dopaminergic neurons
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
AU780408B2 (en) * 1999-06-08 2005-03-17 Calibre Biotechnology Pty Limited Small cyclic mimics of brain-derived neurotrophic factor (BDNF)
CA2383076A1 (fr) * 1999-09-16 2001-03-22 Neurotrophic Bioscience, Inc. Facteurs stimulant la survie de neurones dopaminergiques et leur utilisation
EP1262189A1 (fr) * 2000-03-06 2002-12-04 Sumitomo Pharmaceuticals Company, Limited Agents d'amelioration de la resistance a la leptine
US6784335B2 (en) 2000-06-29 2004-08-31 Deltagen, Inc. Transgenic mice containing BMP gene disruptions
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7491810B2 (en) 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7615676B2 (en) 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
AU2003286833A1 (en) * 2002-11-01 2004-06-07 University Of Medicine And Dentistry Of New Jersey A method for increasing synaptic growth or plasticity
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
WO2005025605A1 (fr) * 2003-09-09 2005-03-24 Two Cells Co. Ltd. Remede et methode therapeutique pour des parodontopathies et des maladies de la pulpe dentaire
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2006119434A2 (fr) * 2005-05-02 2006-11-09 University Of Southern California Marqueurs de methylation d'adn associes au phenotype de methylateur d'ilot cpg (cimp) dans le cancer colorectal humain
EP2465924A3 (fr) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Cellules isolées et populations les comportant pour le traitement des maladies du SNC
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
WO2007066338A1 (fr) * 2005-12-08 2007-06-14 Ramot At Tel Aviv University Ltd. Cellules de type oligodendrocytes isolées et populations les comprenant pour le traitement de maladies du système nerveux central
US20100035877A1 (en) * 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CA2694762A1 (fr) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Procedes et compositions destines a augmenter une activite a-iduronidase dans le snc
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
EP3514229A1 (fr) 2008-05-28 2019-07-24 Ramot at Tel-Aviv University Ltd. Cellules souches mésenchymateuses destinées au traitement de troubles du snc
CA2748889A1 (fr) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions et procedes pour le transport de proteines de fusion igg-recepteur leurre a travers la barriere hemato-encephalique
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
EP2594295A1 (fr) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Implants nerveux basés sur un biomatériau compact contenant des cellules
EP4338797A3 (fr) 2011-12-02 2024-06-12 Armagen, Inc. Procédés et compositions pour augmenter l'activité d'arylsulfatase a dans le snc
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
JP2020531041A (ja) * 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
CN116543838B (zh) * 2023-07-05 2023-09-05 苏州凌点生物技术有限公司 一种生物基因选择表达概率的数据分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3123963C2 (de) * 1981-06-19 1985-05-15 Berchem & Schaberg Gmbh, 4650 Gelsenkirchen Gesteinsschneidkopf für einen Schneidkopf-Saugbagger
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
CA1310602C (fr) * 1986-06-03 1992-11-24 Hajime Horii Promoteur de la levure et procede pour la preparation de proteines heterologues
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins

Also Published As

Publication number Publication date
DK0440777T3 (da) 1997-04-21
CA2040412C (fr) 2003-03-18
SK422990A3 (en) 1999-02-11
PT95152A (pt) 1991-05-22
EP0440777A1 (fr) 1991-08-14
WO1991003568A1 (fr) 1991-03-21
DE69029934D1 (de) 1997-03-27
US5438121A (en) 1995-08-01
DE69029934T2 (de) 1997-07-24
FI912104A0 (fi) 1991-04-30
AU647412B2 (en) 1994-03-24
ATE148921T1 (de) 1997-02-15
US5229500A (en) 1993-07-20
CN1124343C (zh) 2003-10-15
FI105342B (fi) 2000-07-31
CN1052142A (zh) 1991-06-12
NO911689D0 (no) 1991-04-29
AU6337390A (en) 1991-04-08
PT95152B (pt) 1998-06-30
LV10725A (lv) 1995-06-20
ES2098271T3 (es) 1997-05-01
SG46954A1 (en) 1998-03-20
IE903128A1 (en) 1991-03-13
EP0440777B1 (fr) 1997-02-12
KR920701432A (ko) 1992-08-11
NO911689L (no) 1991-06-25
HK1006578A1 (en) 1999-03-05
LV10725B (en) 1995-12-20
CA2040412A1 (fr) 1991-03-01
KR100188189B1 (en) 1999-06-01
EP0440777A4 (en) 1992-05-13
SK279668B6 (sk) 1999-02-11
NO303584B1 (no) 1998-08-03

Similar Documents

Publication Publication Date Title
KR100188189B1 (en) Brain derived neutrophic factor
GR900100653A (el) Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.
Maruyama et al. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells
EP0666912B1 (fr) Facteurs neurotrophiques ciliaires modifies
EP0448707A4 (en) Ciliary neurotrophic factor
HUP0300067A2 (en) Novel method for down-regulation of amyloid
IL95480A0 (en) Process for the preparation of cyclic amino acids,and intermediates
SI0852585T1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
FR2637612B1 (fr) Sequences de nucleotides codant pour une proteine a activite ureasique
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
NZ275772A (en) Haemophilus transferrin receptor genes and proteins including production and use
HUP9800377A1 (hu) Új növekedési faktor és ezt kódoló génszekvencia
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
Mann et al. Isolation of native microtubules from porcine brain and characterization of SH groups essential for polymerization at the GTP binding sites
KR100245250B1 (en) Human follicle stimulating hormone receptor
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
CA2047718A1 (fr) Facteur neurotrophique ciliaire purifie
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
Barde et al. Brain derived neurotrophic factor
DE69730967D1 (en) Human dnase ii
ATE101521T1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
DE3722673A1 (de) Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
KB Patent renewed